title: High-dose rituximab does not negatively affect peripheral blood stem cell mobilization kinetics in patients with intermediate-grade non-Hodgkin's lymphoma.
abstract: Rituximab, an anti-CD20 human-mouse chimeric monoclonal antibody has been shown to improve response rates when it is combined with standard salvage chemotherapy in patients with relapsed or refractory intermediate-grade B-cell non-Hodgkin's lymphoma. A vast majority of these patients subsequently undergo high-dose therapy followed by stem cell transplantation. However, the impact of rituximab on stem cell mobilization kinetics is not well characterized. The purpose of this study was to study the effect of high-dose rituximab given with chemotherapy on stem cell mobilization in patients with intermediate-grade B-cell non-Hodgkin's lymphoma. Thirty-six patients received ifosfamide, etoposide, and rituximab followed by filgrastim for stem cell mobilization. The chemotherapy regimen was well tolerated. Thirty-four of 36 patients (94%) were able to mobilize at least 2 x 10(6) CD34+ cells/kg body weight after a median of 2 apheresis procedures. The median CD34+ cell dose collected per kilogram of recipient body weight was 6.5 x 10(6) (range, 4.65-31.15). All patients who subsequently underwent high-dose chemotherapy and stem cell transplantation experienced sustained engraftment. In conclusion, high-dose rituximab given during stem cell mobilization does not negatively affect stem cell mobilization kinetics.
authors.affiliation: Department of Blood and Marrow Transplantation, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA. cmhosing@mdanderson.org
authors.forename: Chitra
authors.initials: C
authors.lastname: Hosing
authors.forename: Rima M
authors.initials: RM
authors.lastname: Saliba
authors.forename: Martin
authors.initials: M
authors.lastname: Körbling
authors.forename: Sandra
authors.initials: S
authors.lastname: Acholonu
authors.forename: John
authors.initials: J
authors.lastname: McMannis
authors.forename: Paolo
authors.initials: P
authors.lastname: Anderlini
authors.forename: Sergio
authors.initials: S
authors.lastname: Giralt
authors.forename: Marcos
authors.initials: M
authors.lastname: De Lima
authors.forename: Grace-Julia
authors.initials: GJ
authors.lastname: Okoroji
authors.forename: Daniel R
authors.initials: DR
authors.lastname: Couriel
authors.forename: Richard
authors.initials: R
authors.lastname: Champlin
authors.forename: Issa F
authors.initials: IF
authors.lastname: Khouri
authors.forename: Michele L
authors.initials: ML
authors.lastname: Donato
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000096:biosynthesis; D018952:Antigens, CD34 / Q000096:biosynthesis; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D007155:Immunologic Factors / Q000008:administration & dosage; D007700:Kinetics; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D000069283:Rituximab; D033581:Stem Cell Transplantation / Q000379:methods; D013234:Stem Cells / Q000166:cytology / Q000187:drug effects*
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D018952:Antigens, CD34; D000970:Antineoplastic Agents; D007155:Immunologic Factors; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D000069283:Rituximab; D005047:Etoposide; D000069585:Filgrastim; D007069:Ifosfamide